Evidence map›Paper›PMID 29200861›Full record

ArticleTherapeutics and clinical risk management2017

Statin therapy for preventing cardiovascular diseases in patients treated with tacrolimus after kidney transplantation.

Nayoung Han, Seung Hee Han, Yun-Kyoung Song, Myeong Gyu Kim, Yon Su Kim, In-Wha Kim, Jung Mi Oh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutics and clinical risk management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nayoung Han *Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul.
Seung Hee Han *Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul.
Yun-Kyoung SongResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul.
Myeong Gyu KimResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul.
Yon Su KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul.
In-Wha Kim *Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul.
Jung Mi Oh *Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul.
Seoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLipid abnormalities are prevalent in tacrolimus-treated patients. The aim of the study was to evaluate the preventive effects of statin therapy on major adverse cardiovascular events (MACE) in patients treated with tacrolimus-based immunosuppression after kidney transplantation (KT), and to identify the risk factors.

methodsThis observational cohort study included adult patients who underwent KT and were treated with tacrolimus. Patients who received any lipid-lowering agents except statins, or had a history of immunosuppressant use before transplantation were excluded. The primary outcome was the adjusted risk of the first occurrence of MACE. The secondary outcomes included the risk of individual cardiovascular disease (CVD) and changes in cholesterol level. Subgroup analyses were performed in the statin-user group according to the dosage and/or type of statin.

resultsCompared with the control group (n=73), the statin-users (n=92) had a significantly reduced risk of MACE (adjusted HR, 0.31; 95% CI, 0.13-0.74). In the Cox regression analysis, old age, history of CVD, and comorbid hypertension were identified as independent factors associated with increased MACE. The total cholesterol levels were not significantly different between the two groups. Subjects with higher cumulative defined daily dose of statins had significantly lower risks of MACE.

conclusionStatin therapy in patients treated with tacrolimus after KT significantly lowered the risk of MACE. Long-term statin therapy is clearly indicated in older kidney transplant recipients for secondary prevention.

Indexed as

HMG-CoA reductase inhibitorskidney transplantationmajor adverse cardiovascular events (MACE)tacrolimus

Identifiers

PMID29200861
PMCPMC5701562
OpenAlexW2768814885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.